SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors have been approved to reduce major cardiovascular events in patients with diabetes though direct mechanisms not necessarily related to their hypoglycemic effects (Kaplan et al., 2018; Scheen, 2018).